NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

尖端醫療醫藥品(ATMP)市場:各治療產品(細胞,遺傳基因,CAR-T,組織工程),地區/主要國家的市場分析、預測(2021年∼2031年),主要企業,COVID-19復甦情境

Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031: Forecasts by Therapy Products (Cell, Gene, CAR-T, Tissue Engineered), Regional & Leading National Market Analysis, Leading ATMP Companies, COVID-19 Recovery Scenarios

出版商 Visiongain Ltd 商品編碼 983585
出版日期 內容資訊 英文 380 Pages
商品交期: 最快1-2個工作天內
價格
尖端醫療醫藥品(ATMP)市場:各治療產品(細胞,遺傳基因,CAR-T,組織工程),地區/主要國家的市場分析、預測(2021年∼2031年),主要企業,COVID-19復甦情境 Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031: Forecasts by Therapy Products (Cell, Gene, CAR-T, Tissue Engineered), Regional & Leading National Market Analysis, Leading ATMP Companies, COVID-19 Recovery Scenarios
出版日期: 2020年11月24日內容資訊: 英文 380 Pages
簡介

本報告提供全球尖端醫療醫藥品(ATMP)市場的相關調查,市場規模,至2031年的收益預測,成長及阻礙因素,市場佔有率和競爭情形,COVID-19的影響,各產品簡介,治療藥品、地區的市場分析,機會和課題,主要企業的簡介等資訊。

目錄

第1章 報告概要

第2章 摘要整理

第3章 ATMP市場簡介

  • ATMP:市場區隔
    • 細胞治療藥品
    • 基因治療藥品
    • CAR-T治療藥品
    • 組織工程藥品
  • 市場動態:全球ATMP市場
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 已批准ATMP(2015-2019)
  • STEP分析
  • 供應鏈
  • 法規環境:ATMP
  • ATMP市場趨勢(2020)
  • 冠狀病毒的影響(COVID-19)
    • 考慮COVID-19可能的影響情境

第4章 市場分析:各治療藥品(2020年∼2031年)

  • 全球主要市場(2021)
  • 全球市場:冠狀病毒影響情境
  • 細胞治療產品
  • 基因治療產品
  • CAR-T治療產品
  • 組織工程產品

第5章 市場分析:各地區(2020年∼2031年)

  • 市場概要
  • 市場區隔
    • 市場佔有率的變化(2020,2026,2031)
  • 全球市場:冠狀病毒的影響情境

第6章 北美

第7章 歐洲

第8章 亞太地區

第9章 南美

第10章 中東和非洲

第11章 市場分析

  • 企業佔有率分析(2020)

第12章 企業簡介

  • Bluebird bio, Inc.
  • Bristol Myers-Squibb (Celgene Corporation)
  • Gilead Sciences, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Kolon TissueGene, Inc.
  • MEDIPOST
  • Novartis AG
  • Organogenesis Holdings, Inc.
  • PHARMICELL Co., Ltd.
  • Spark Therapeutics, Inc.
  • uniQure N.V.
  • Vericel Corporation

第13章 結論

  • 目前市場情況與市場預測概要(2020年∼2031年)
  • 各治療藥品:全球主要ATMP市場
  • 全球ATMP市場主要地區
  • 建議

第14章 詞彙表

第15章 企業和組織的清單

  • 企業的清單
  • 組織的清單
目錄
Product Code: PHA1019

Title:
Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031
Forecasts by Therapy Products (Cell Therapy Products, Gene Therapy Products, CAR-T Therapy Products and Tissue Engineered Products). Regional and Leading National Market Analysis PLUS Analysis of Leading ATMP Companies AND COVID-19 Recovery Scenarios.

Global Advanced Therapy Medicinal Products Market - our new study reveals trends, R&D progress, and predicted revenues

How will the global ATMP industry evolve during the forecast period from 2021-2031? If you are involved in this sector you must read this newly updated report. As the report provides details about the commercial trends, market shares, industrial activities, revenues, economic and social landscapes and other factors. Visiongain's report shows you the potential revenues streams to 2031, assessing data, trends, opportunities and business prospects there. In addition, the report would also help you to enhance your strategic decision making, strengthen the analysis of competitors, allows you to formulate growth strategies, and maximise profitability of the company.

Discover how to stay ahead

Our 380 pages report provides 226 tables and 211 charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing ATMP Market. See how to exploit the opportunities.

Forecasts to 2031 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), STEP Analysis, Supply Chain Analysis, product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Global ATMP Market: By Therapy Products

  • Cell Therapy Products
  • Gene Therapy Products
  • CAR-T Therapy Products
  • Tissue Engineered Products

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East and Africa

  • UAE
  • Africa
  • Rest of Middle East and Africa

The report also includes profiles and for some of the leading companies in the Global ATMP Market, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth

Overall world revenue for ATMP Market will surpass $xx billion in 2021, our work calculates it grow in near future. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Global ATMP Market report helps you

In summary, our 380 page report provides you with the following knowledge:

  • Revenue forecasts to 2031 for Global ATMP Market, with forecasts for Therapy Products, each forecasted at a global and regional level- discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2031 for 5 regional and 20 key national markets - See forecasts for the ATMP market in North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market- including company profiles for 12 of the major companies involved in the Global ATMP Market. Some of the company's profiled in this report include Bluebird bio, Inc., Gilead Sciences, Inc., JCR Pharmaceuticals, Co. Ltd., MEDIPOST, PHARMICELL Co. Ltd., Spark Therapeutics, Vericel Corporation and others.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Global ATMP Market and leading companies. You will find data, trends and predictions.

Buy our report today Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031: Forecasts by Therapy Products (Cell Therapy Products, Gene Therapy Products, CAR-T Therapy Products and Tissue Engineered Products). Regional and Leading National Market Analysis PLUS Analysis of Leading ATMP Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed - order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Advanced Therapy Medicinal Products Market Overview
  • 1.2. Global Advanced Therapy Medicinal Products Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Executive Summary

3. Introduction to ATMP Market

  • 3.1. ATMP: Market Segmentation
    • 3.1.1. Cell Therapy Products
    • 3.1.2. Gene Therapy Products
    • 3.1.3. CAR-T Therapy Products
    • 3.1.4. Tissue Engineered Products
  • 3.2. Market Dynamics: Global ATMP Market
    • 3.2.1. Drivers
      • 3.2.1.1. Rising preference for advanced therapies
      • 3.2.1.2. Rising prevalence of chronic and genetic disorders
      • 3.2.1.3. Increasing number of clinical trials in ATMP segment
      • 3.2.1.4. Rising demand for organ transplantation
    • 3.2.2. Restraints
      • 3.2.2.1. High cost of therapy products
      • 3.2.2.2. Stringent regulatory norms
    • 3.2.3. Opportunities
      • 3.2.3.1. Increasing health benefits
      • 3.2.3.2. Growing economies and demographics in Asia-Pacific
      • 3.2.3.3. Rising applications of ATMP in various indications
        • 3.2.3.3.1. Ageing increases the risk for Alzheimer's
        • 3.2.3.3.2. Increasing development for the treatment of Cystic Fibrosis
        • 3.2.3.3.3. Increasing number of clinical trials for the treatment of Muscular Dystrophies
        • 3.2.3.3.4. Rising prevalence of Hemophilia
  • 3.3. Approved ATMPs 2015-2019
  • 3.4. STEP Analysis: Global ATMP Market
    • 3.4.1. Social Factors Impacting the ATMP Market
    • 3.4.2. Technological Factors Impacting the ATMP Market
    • 3.4.3. Economical Factors Impacting the ATMP Market
    • 3.4.4. Political Factors Impacting the ATMP Market
  • 3.5. Supply Chain: Global ATMP Market
  • 3.6. Regulatory Environment: ATMP
  • 3.7. Trends in Global ATMP Market 2020
  • 3.8. Impact of Coronavirus (COVID-19)
    • 3.8.1. Possible impact scenarios of COVID-19
      • 3.8.1.1. 'V' shaped recovery model
      • 3.8.1.2. 'U' shaped recovery model
      • 3.8.1.3. 'L' shaped recovery model
      • 3.8.1.4. 'W' shaped recovery model
      • 3.8.1.5. Conclusion

4. Global Advanced Therapy Medicinal Products Market by Therapy Products, 2020-2031

  • 4.1. Leading Advanced Therapy Medicinal Products Market, by Therapy Products in 2021
  • 4.2. Global ATMP Market, by Therapy Products - Coronavirus Impact Scenario
    • 4.2.1. Global ATMP Market, by Therapy Products (V - Shaped Recovery Model)
    • 4.2.2. Global ATMP Market, by Therapy Products (U - Shaped Recovery Model)
    • 4.2.3. Global ATMP Market, by Therapy Products (L - Shaped Recovery Model)
    • 4.2.4. Global ATMP Market, by Therapy Products (W - Shaped Recovery Model)
  • 4.3. Cell Therapy Products
    • 4.3.1. Cell Therapy Products Market - Coronavirus Impact Scenario
      • 4.3.1.1. 'V' Shaped Recovery Model
      • 4.3.1.2. 'U' Shaped Recovery Model
      • 4.3.1.3. 'L' Shaped Recovery Model
      • 4.3.1.4. 'W' Shaped Recovery Model
  • 4.4. Gene Therapy Products
    • 4.4.1. Gene Therapy Products Market - Coronavirus Impact Scenario
      • 4.4.1.1. 'V' Shaped Recovery Model
      • 4.4.1.2. 'U' Shaped Recovery Model
      • 4.4.1.3. 'L' Shaped Recovery Model
      • 4.4.1.4. 'W' Shaped Recovery Model
  • 4.5. CAR-T Therapy Products
    • 4.5.1. CAR-T Therapy Products Market - Coronavirus Impact Scenario
      • 4.5.1.1. 'V' Shaped Recovery Model
      • 4.5.1.2. 'U' Shaped Recovery Model
      • 4.5.1.3. 'L' Shaped Recovery Model
      • 4.5.1.4. 'W' Shaped Recovery Model
  • 4.6. Tissue Engineered Products
    • 4.6.1. Tissue Engineered Products Market - Coronavirus Impact Scenario
      • 4.6.1.1. 'V' Shaped Recovery Model
      • 4.6.1.2. 'U' Shaped Recovery Model
      • 4.6.1.3. 'L' Shaped Recovery Model
      • 4.6.1.4. 'W' Shaped Recovery Model

5. Global ATMP Market by Regions, 2020-2031

  • 5.1. The ATMP Market Overview
  • 5.2. Segmenting the Global ATMP Market
    • 5.2.1. Changes in the Global ATMP Market Share - 2020, 2026 and 2031
  • 5.3. Global ATMP Market, by Geography - Coronavirus Impact Scenario
    • 5.3.1. 'V' Shaped Recovery Model
    • 5.3.2. 'U' Shaped Recovery Model
    • 5.3.3. 'L' Shaped Recovery Model
    • 5.3.4. 'W' Shaped Recovery Model

6. North America ATMP Market

  • 6.1. North America ATMP Market by Therapy Product
  • 6.2. North America ATMP Market by Therapy Product (V - Shaped Recovery Model)
  • 6.3. North America ATMP Market by Therapy Product (U - Shaped Recovery Model)
  • 6.4. North America ATMP Market by Therapy Product (L - Shaped Recovery Model)
  • 6.5. North America ATMP Market by Therapy Product (W - Shaped Recovery Model)
  • 6.6. North America ATMP Market by Country
  • 6.7. North America ATMP Market, Coronavirus Impact Scenario
    • 6.7.1. 'V' Shaped Recovery Model
    • 6.7.2. 'U' Shaped Recovery Model
    • 6.7.3. 'L' Shaped Recovery Model
    • 6.7.4. 'W' Shaped Recovery Model
    • 6.7.5. Growing Demand for Clinical Trials in U.S. to Augur Market Growth
      • 6.7.5.1. U.S. ATMP Market Forecast, 2021-2031
      • 6.7.5.2. U.S. ATMP Market, Coronavirus Impact Scenario
        • 6.7.5.2.1. 'V' Shaped Recovery Model
        • 6.7.5.2.2. 'U' Shaped Recovery Model
        • 6.7.5.2.3. 'L' Shaped Recovery Model
        • 6.7.5.2.4. 'W' Shaped Recovery Model
    • 6.7.6. Rising government support drives the growth in Canada
      • 6.7.6.1. Canada ATMP Market, Coronavirus Impact Scenario
        • 6.7.6.1.1. 'V' Shaped Recovery Model
        • 6.7.6.1.2. 'U' Shaped Recovery Model
        • 6.7.6.1.3. 'L' Shaped Recovery Model
        • 6.7.6.1.4. 'W' Shaped Recovery Model

7. Europe

  • 7.1. Market Authorisations in Europe
  • 7.2. Europe ATMP Market by Product
  • 7.3. Europe ATMP Market by Therapy Product (V - Shaped Recovery Model)
  • 7.4. Europe ATMP Market by Therapy Product (U - Shaped Recovery Model)
  • 7.5. Europe ATMP Market by Therapy Product (L - Shaped Recovery Model)
  • 7.6. Europe ATMP Market by Therapy Product (W - Shaped Recovery Model)
  • 7.7. Europe ATMP Market by Country
  • 7.8. Europe ATMP Market, by Country - Coronavirus Impact Scenario
    • 7.8.1. 'V' Shaped Recovery Model
    • 7.8.2. 'U' Shaped Recovery Model
    • 7.8.3. 'L' Shaped Recovery Model
    • 7.8.4. 'W' Shaped Recovery Model
    • 7.8.5. Increasing number of ATMPs in Germany propels the market growth
      • 7.8.5.1. Germany ATMP Market, Coronavirus Impact Scenario
        • 7.8.5.1.1. 'V' Shaped Recovery Model
        • 7.8.5.1.2. 'U' Shaped Recovery Model
        • 7.8.5.1.3. 'L' Shaped Recovery Model
        • 7.8.5.1.4. 'W' Shaped Recovery Model
    • 7.8.6. Increasing access to ATMP in the U.K. drives the market
      • 7.8.6.1. U.K. ATMP Market, Coronavirus Impact Scenario
        • 7.8.6.1.1. 'V' Shaped Recovery Model
        • 7.8.6.1.2. 'U' Shaped Recovery Model
        • 7.8.6.1.3. 'L' Shaped Recovery Model
        • 7.8.6.1.4. 'W' Shaped Recovery Model
    • 7.8.7. Growing popularity of ATMP in France propels the market growth
      • 7.8.7.1. France ATMP Market, Coronavirus Impact Scenario
        • 7.8.7.1.1. 'V' Shaped Recovery Model
        • 7.8.7.1.2. 'U' Shaped Recovery Model
        • 7.8.7.1.3. 'L' Shaped Recovery Model
        • 7.8.7.1.4. 'W' Shaped Recovery Model
    • 7.8.8. Increasing number of clinical trials in Italy is one of the prominent factors for the growth of ATMP
      • 7.8.8.1. Italy ATMP Market, Coronavirus Impact Scenario
        • 7.8.8.1.1. 'V' Shaped Recovery Model
        • 7.8.8.1.2. 'U' Shaped Recovery Model
        • 7.8.8.1.3. 'L' Shaped Recovery Model
        • 7.8.8.1.4. 'W' Shaped Recovery Model
    • 7.8.9. Favourable government regulations in Spain supports the market growth
      • 7.8.9.1. Spain ATMP Market, Coronavirus Impact Scenario
        • 7.8.9.1.1. 'V' Shaped Recovery Model
        • 7.8.9.1.2. 'U' Shaped Recovery Model
        • 7.8.9.1.3. 'L' Shaped Recovery Model
        • 7.8.9.1.4. 'W' Shaped Recovery Model
    • 7.8.10. Rest of Europe
      • 7.8.10.1. Rest of Europe ATMP Market, Coronavirus Impact Scenario
        • 7.8.10.1.1. 'V' Shaped Recovery Model
        • 7.8.10.1.2. 'U' Shaped Recovery Model
        • 7.8.10.1.3. 'L' Shaped Recovery Model
        • 7.8.10.1.4. 'W' Shaped Recovery Model

8. Asia-Pacific

  • 8.1. Asia-Pacific ATMP Market by Therapy Product
  • 8.2. Asia-Pacific ATMP Market by Therapy Product (V - Shaped Recovery Model)
  • 8.3. Asia-Pacific ATMP Market by Therapy Product (U - Shaped Recovery Model)
  • 8.4. Asia-Pacific ATMP Market by Therapy Product (L - Shaped Recovery Model)
  • 8.5. Asia-Pacific ATMP Market by Therapy Product (W - Shaped Recovery Model)
  • 8.6. Asia-Pacific ATMP Market by Country
  • 8.7. Asia-Pacific ATMP Market, Coronavirus Impact Scenario
    • 8.7.1. 'V' Shaped Recovery Model
    • 8.7.2. 'U' Shaped Recovery Model
    • 8.7.3. 'L' Shaped Recovery Model
    • 8.7.4. 'W' Shaped Recovery Model
    • 8.7.5. Increasing healthcare spending in Japan propels the market growth
      • 8.7.5.1. Japan ATMP Market, Coronavirus Impact Scenario
        • 8.7.5.1.1. 'V' Shaped Recovery Model
        • 8.7.5.1.2. 'U' Shaped Recovery Model
        • 8.7.5.1.3. 'L' Shaped Recovery Model
        • 8.7.5.1.4. 'W' Shaped Recovery Model
    • 8.7.6. Rising research and development investments supports the growth in China
      • 8.7.6.1. China ATMP Market, Coronavirus Impact Scenario
        • 8.7.6.1.1. 'V' Shaped Recovery Model
        • 8.7.6.1.2. 'U' Shaped Recovery Model
        • 8.7.6.1.3. 'L' Shaped Recovery Model
        • 8.7.6.1.4. 'W' Shaped Recovery Model
    • 8.7.7. Growing healthcare awareness in India drive the market growth
      • 8.7.7.1. India ATMP Market, Coronavirus Impact Scenario
        • 8.7.7.1.1. 'V' Shaped Recovery Model
        • 8.7.7.1.2. 'U' Shaped Recovery Model
        • 8.7.7.1.3. 'L' Shaped Recovery Model
        • 8.7.7.1.4. 'W' Shaped Recovery Model
    • 8.7.8. Rest of Asia-Pacific
      • 8.7.8.1. Rest of Asia-Pacific ATMP Market, Coronavirus Impact Scenario
        • 8.7.8.1.1. 'V' Shaped Recovery Model
        • 8.7.8.1.2. 'U' Shaped Recovery Model
        • 8.7.8.1.3. 'L' Shaped Recovery Model
        • 8.7.8.1.4. 'W' Shaped Recovery Model

9. Latin America

  • 9.1. Latin America ATMP Market by Therapy Product
  • 9.2. Latin America ATMP Market by Therapy Product (V - Shaped Recovery Model)
  • 9.3. Latin America ATMP Market by Therapy Product (U - Shaped Recovery Model)
  • 9.4. Latin America ATMP Market by Therapy Product (L - Shaped Recovery Model)
  • 9.5. Latin America ATMP Market by Therapy Product (W - Shaped Recovery Model)
  • 9.6. Latin America ATMP Market by Country
  • 9.7. Latin America ATMP Market, Coronavirus Impact Scenario
    • 9.7.1. 'V' Shaped Recovery Model
    • 9.7.2. 'U' Shaped Recovery Model
    • 9.7.3. 'L' Shaped Recovery Model
    • 9.7.4. 'W' Shaped Recovery Model
    • 9.7.5. Rising number of trials registered in Brazil supports the market growth
      • 9.7.5.1. Brazil ATMP Market, Coronavirus Impact Scenario
        • 9.7.5.1.1. 'V' Shaped Recovery Model
        • 9.7.5.1.2. 'U' Shaped Recovery Model
        • 9.7.5.1.3. 'L' Shaped Recovery Model
        • 9.7.5.1.4. 'W' Shaped Recovery Model
    • 9.7.6. Technological advancements in Mexico propels the growth
      • 9.7.6.1. Mexico ATMP Market, Coronavirus Impact Scenario
        • 9.7.6.1.1. 'V' Shaped Recovery Model
        • 9.7.6.1.2. 'U' Shaped Recovery Model
        • 9.7.6.1.3. 'L' Shaped Recovery Model
        • 9.7.6.1.4. 'W' Shaped Recovery Model
    • 9.7.7. Rest of Latin America
      • 9.7.7.1. Rest of Latin America ATMP Market, Coronavirus Impact Scenario
        • 9.7.7.1.1. 'V' Shaped Recovery Model
        • 9.7.7.1.2. 'U' Shaped Recovery Model
        • 9.7.7.1.3. 'L' Shaped Recovery Model
        • 9.7.7.1.4. 'W' Shaped Recovery Model

10. Middle-East & Africa

  • 10.1. MEA ATMP Market by Therapy Products
  • 10.2. MEA ATMP Market by Therapy Product (V - Shaped Recovery Model)
  • 10.3. MEA ATMP Market by Therapy Product (U - Shaped Recovery Model)
  • 10.4. MEA ATMP Market by Therapy Product (L - Shaped Recovery Model)
  • 10.5. MEA ATMP Market by Therapy Product (W - Shaped Recovery Model)
  • 10.6. MEA ATMP Market by Country
  • 10.7. MEA ATMP Market, Coronavirus Impact Scenario
    • 10.7.1. 'V' Shaped Recovery Model
    • 10.7.2. 'U' Shaped Recovery Model
    • 10.7.3. 'L' Shaped Recovery Model
    • 10.7.4. 'W' Shaped Recovery Model
    • 10.7.5. Rising demand for healthcare products in UAE supports the market growth
      • 10.7.5.1. UAE ATMP Market, Coronavirus Impact Scenario
        • 10.7.5.1.1. 'V' Shaped Recovery Model
        • 10.7.5.1.2. 'U' Shaped Recovery Model
        • 10.7.5.1.3. 'L' Shaped Recovery Model
        • 10.7.5.1.4. 'W' Shaped Recovery Model
    • 10.7.6. Increasing healthcare spending in South Africa drives the market growth
      • 10.7.6.1. South Africa ATMP Market, Coronavirus Impact Scenario
        • 10.7.6.1.1. 'V' Shaped Recovery Model
        • 10.7.6.1.2. 'U' Shaped Recovery Model
        • 10.7.6.1.3. 'L' Shaped Recovery Model
        • 10.7.6.1.4. 'W' Shaped Recovery Model
    • 10.7.7. Rest of MEA
      • 10.7.7.1. Rest of MEA ATMP Market, Coronavirus Impact Scenario
        • 10.7.7.1.1. 'V' Shaped Recovery Model
        • 10.7.7.1.2. 'U' Shaped Recovery Model
        • 10.7.7.1.3. 'L' Shaped Recovery Model
        • 10.7.7.1.4. 'W' Shaped Recovery Model

11. Market Analysis

  • 11.1. Company Share Analysis, 2020

12. Company Profiles

  • 12.1. Bluebird bio, Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Company Snapshot, 2020
    • 12.1.3. Financial Outlook, 2015-2019
    • 12.1.4. Product Portfolio
    • 12.1.5. Strategic Developments, 2019-2020
  • 12.2. Bristol Myers-Squibb (Celgene Corporation)
    • 12.2.1. Company Overview
    • 12.2.2. Company Snapshot
    • 12.2.3. Financial Outlook, 2015-2019
    • 12.2.4. Product Portfolio
    • 12.2.5. Strategic Developments, 2019
  • 12.3. Gilead Sciences, Inc.
    • 12.3.1. Company Overview
    • 12.3.2. Company Snapshot
    • 12.3.3. Financial Outlook, 2015-2019
    • 12.3.4. Product Portfolio
    • 12.3.5. Strategic Developments, 2020
  • 12.4. JCR Pharmaceuticals Co., Ltd.
    • 12.4.1. Company Overview
    • 12.4.2. Company Outlook
    • 12.4.3. Financial Outlook, 2015-2019
    • 12.4.4. Product Portfolio
    • 12.4.5. Strategic Developments, 2018
  • 12.5. Kolon TissueGene, Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Company Snapshot
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Developments, 2018-2020
  • 12.6. MEDIPOST
    • 12.6.1. Company Overview
    • 12.6.2. Company Snapshot
    • 12.6.3. Financial Outlook, 2017-2019
    • 12.6.4. Product Portfolio
    • 12.6.5. Strategic Developments, 2018-2020
  • 12.7. Novartis AG
    • 12.7.1. Company Overview
    • 12.7.2. Company Snapshot
    • 12.7.3. Financial Outlook, 2015-2019
    • 12.7.4. Product Portfolio
    • 12.7.5. Strategic Developments, 2018-2020
  • 12.8. Organogenesis Holdings, Inc.
    • 12.8.1. Company Overview
    • 12.8.2. Company Snapshot
    • 12.8.3. Financial Outlook, 2017-2019
    • 12.8.4. Product Portfolio
  • 12.9. PHARMICELL Co., Ltd.
    • 12.9.1. Company Overview
    • 12.9.2. Company Snapshot
    • 12.9.3. Product Portfolio
  • 12.10. Spark Therapeutics, Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Company Snapshot
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Developments, 2018-2019
  • 12.11. uniQure N.V.
    • 12.11.1. Company Overview
    • 12.11.2. Company Snapshot
    • 12.11.3. Financial Outlook, 2015-2019
    • 12.11.4. Product Portfolio
    • 12.11.5. Strategic Developments, 2018-2019
  • 12.12. Vericel Corporation
    • 12.12.1. Company Overview
    • 12.12.2. Company Snapshot
    • 12.12.3. Financial Outlook, 2015-2019
    • 12.12.4. Product Portfolio
    • 12.12.5. Strategic Developments, 2018

13. Conclusion

  • 13.1. Overview of the Current Market Conditions and Market Forecast, 2020-2031
  • 13.2. Leading Global ATMP Market, by Therapy Product
  • 13.3. Leading Regions in the Global ATMP Market
  • 13.4. Recommendations

14. Glossary

15. List of Companies & Organisations

  • 15.1. List of Companies
  • 15.2. List of Organisations

LIST OF TABLES

  • TABLE 1 GLOBAL ATMP MARKET: REVENUE SNAPSHOT
  • TABLE 2 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V-SHAPED RECOVERY MODEL)
  • TABLE 3 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U-SHAPED RECOVERY MODEL)
  • TABLE 4 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L-SHAPED RECOVERY MODEL)
  • TABLE 5 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W-SHAPED RECOVERY MODEL)
  • TABLE 6 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS MARKET FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 7 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN) AND AGR (%), 2020-2031 (V-SHAPED RECOVERY MODEL)
  • TABLE 8 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 9 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 10 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 11 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 12 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 13 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 14 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L SHAPED RECOVERY MODEL)
  • TABLE 15 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W SHAPED RECOVERY MODEL)
  • TABLE 16 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 17 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V SHAPED RECOVERY MODEL)
  • TABLE 18 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U SHAPED RECOVERY MODEL)
  • TABLE 19 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L SHAPED RECOVERY MODEL)
  • TABLE 20 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W SHAPED RECOVERY MODEL)
  • TABLE 21 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 22 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V SHAPED RECOVERY MODEL)
  • TABLE 23 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U SHAPED RECOVERY MODEL)
  • TABLE 24 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L SHAPED RECOVERY MODEL)
  • TABLE 25 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 26 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 27 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 28 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 29 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 30 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 31 GLOBAL ATMP MARKET AND FORECAST, BY REGION MARKET FORECAST: REVENUE ($ BN), AGR (%), AND CAGR (%), 2020-2031
  • TABLE 32 GLOBAL ATMP MARKET AND FORECAST: MARKET SHARE BY REGION, 2021, 2026 AND 2031
  • TABLE 33 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 34 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 35 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 36 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 37 NORTH AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 38 NORTH AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V- SHAPED RECOVERY MODEL)
  • TABLE 39 NORTH AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U- SHAPED RECOVERY MODEL)
  • TABLE 40 NORTH AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L- SHAPED RECOVERY MODEL)
  • TABLE 41 NORTH AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 42 NORTH AMERICA ATMP MARKET AND FORECAST: BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 43 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 44 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED MARKET RECOVERY MODEL)
  • TABLE 45 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 46 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 47 U.S. ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 48 U.S. ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 49 U.S. ATMP MARKET AND FORECAST, REVENUE ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 50 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 51 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 52 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 53 CANADA ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 54 CANADA ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 55 CANADA ATMP MARKET AND FORECAST, REVENUE ($ B), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 56 CANADA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 57 CANADA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 58 CANADA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 59 EUROPE ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 60 EUROPE ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V- SHAPED RECOVERY MODEL)
  • TABLE 61 EUROPE ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U- SHAPED RECOVERY MODEL)
  • TABLE 62 EUROPE ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L- SHAPED RECOVERY MODEL)
  • TABLE 63 EUROPE ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 64 EUROPE ATMP MARKET AND FORECAST: BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 65 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 66 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 67 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 68 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 69 GERMANY ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 70 GERMANY ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 71 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 72 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 73 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 74 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 75 U.K. ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 76 U.K. ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 77 U.K. ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 78 U.K. ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 79 U.K. ATMP MARKET AND FORECAST REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 80 U.K. ATMP W-SHAPED MARKET SCENARIO AND FORECAST REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 81 FRANCE ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 82 FRANCE ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 83 FRANCE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 84 FRANCE ATMP MARKET AND FORECAST REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 85 FRANCE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 86 FRANCE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 87 ITALY ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 88 ITALY ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 89 ITALY ATMP MARKET AND FORECAST REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 90 ITALY ATMP MARKET AND FORECAST REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 91 ITALY ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 92 ITALY ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 93 SPAIN ATMP MARKET AND FORECAST: REVENUE ($ MN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 94 SPAIN ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 95 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 96 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 97 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 98 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 99 REST OF EUROPE ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 100 REST OF EUROPE ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 101 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 102 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 103 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 104 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 105 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 106 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V- SHAPED RECOVERY MODEL)
  • TABLE 107 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U- SHAPED RECOVERY MODEL)
  • TABLE 108 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L- SHAPED RECOVERY MODEL)
  • TABLE 109 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 110 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 111 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 112 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 113 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 114 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 115 JAPAN ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 116 JAPAN ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 117 JAPAN ATMP MARKET AND FORECAST REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 118 JAPAN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 119 JAPAN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 120 JAPAN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 121 CHINA ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 122 CHINA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 123 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%),2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 124 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 125 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 126 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 127 INDIA ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 128 INDIA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 129 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 130 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 131 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 132 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 133 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 134 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 135 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 136 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 137 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 138 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 139 LATIN AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 140 LATIN AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V- SHAPED RECOVERY MODEL)
  • TABLE 141 LATIN AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U- SHAPED RECOVERY MODEL)
  • TABLE 142 LATIN AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L- SHAPED RECOVERY MODEL)
  • TABLE 143 LATIN AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 144 LATIN AMERICA ATMP MARKET AND FORECAST: BY COUNTRY REVENUE ($ MN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 145 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 146 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 147 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 148 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 149 BRAZIL ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 150 BRAZIL ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 151 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 152 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 153 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 154 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 155 MEXICO ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 156 MEXICO ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 157 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 158 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 159 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-20301 (L - SHAPED RECOVERY MODEL)
  • TABLE 160 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 161 REST OF LATIN AMERICA ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 162 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 163 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 164 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL
  • TABLE 165 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 166 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 167 MEA ATMP MARKET AND FORECAST: BY THERAPY PRODUCTS, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 168 MEA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V- SHAPED RECOVERY MODEL)
  • TABLE 169 MEA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U- SHAPED RECOVERY MODEL)
  • TABLE 170 MEA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L- SHAPED RECOVERY MODEL)
  • TABLE 171 MEA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 172 MEA ATMP MARKET AND FORECAST: BY COUNTRY REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 173 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 174 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 175 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 176 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 177 UAE ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 178 UAE ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 179 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 180 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 181 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 182 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 183 SOUTH AFRICA ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 184 SOUTH AFRICA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 185 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 186 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 187 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 188 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 189 REST OF MEA ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 190 REST OF MEA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
  • TABLE 191 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • TABLE 192 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • TABLE 193 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • TABLE 194 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • TABLE 195 BLUEBIRD BIO, INC.: KEY FACTS, 2020
  • TABLE 196 BLUEBIRD BIO, INC.: HISTORICAL REVENUE ($ TH), 2015-2019
  • TABLE 197 BLUEBIRD BIO, INC.: STRATEGIC DEVELOPMENTS, 2019-2020
  • TABLE 198 BMS: KEY FACTS, 2020
  • TABLE 199 BMS: NUTRITIONAL'S SEGMENT REVENUE ($ MN), 2015-2019
  • TABLE 200 BMS: STRATEGIC DEVELOPMENTS, 2019
  • TABLE 201 GILEAD SCIENCES, INC.: KEY FACTS, 2020
  • TABLE 202 GILEAD SCIENCES: REVENUE ($ BN), 2015-2019
  • TABLE 203 GILEAD SCIENCES: STRATEGIC DEVELOPMENTS, 2020
  • TABLE 204 JCR PHARMACEUTICALS: KEY FACTS, 2020
  • TABLE 205 JCR PHARMACEUTICALS: REVENUE ($ BN), 2015-2019
  • TABLE 206 JCR PHARMACEUTICALS: STRATEGIC DEVELOPMENTS, 2018
  • TABLE 207 KOLON TISSUEGENE, INC.: KEY FACTS, 2020
  • TABLE 208 KOLON TISSUEGENE, INC.: STRATEGIC DEVELOPMENTS, 2018-2020
  • TABLE 209 MEDIPOST: KEY FACTS, 2020
  • TABLE 210 MEDIPOST: REVENUE ($ MN), 2017-2019
  • TABLE 211 MEDIPOST: STRATEGIC DEVELOPMENTS, 2018-2020
  • TABLE 212 NOVARTIS AG: KEY FACTS, 2020
  • TABLE 213 NOVARTIS AG: REVENUE ($ MN), 2015-2019
  • TABLE 214 NOVARTIS AG: STRATEGIC DEVELOPMENTS, 2018-2020
  • TABLE 215 ORGANOGENESIS HOLDINGS, INC.: KEY FACTS, 2020
  • TABLE 216 ORGANOGENESIS: REVENUE ($ TH), 2017-2019
  • TABLE 217 PHARMICELL CO. LTD.: KEY FACTS, 2020
  • TABLE 218 SPARK THERAPEUTICS: KEY FACTS, 2020
  • TABLE 219 SPARK THERAPEUTICS: STRATEGIC DEVELOPMENTS, 2018-2019
  • TABLE 220 UNIQURE N.V.: KEY FACTS, 2020
  • TABLE 221 UNIQURE N.V.: REVENUE ($ TH), 2015-2019
  • TABLE 222 UINQURE N.V.: STRATEGIC DEVELOPMENTS, 2018-2019
  • TABLE 223 VERICEL CORPORATION: KEY FACTS, 2020
  • TABLE 224 VERICEL CORPORATION: REVENUE ($ TH), 2015-2019
  • TABLE 225 VERICEL CORPORATION: STRATEGIC DEVELOPMENTS, 2018
  • TABLE 226 GLOBAL ATMP: MARKET REVENUE AND FORECAST ($ BN), CAGR (%), 2021, 2026 AND 2031

LIST OF FIGURES

  • FIGURE 1 GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET SEGMENTATION, 2020
  • FIGURE 2 MARKET DYNAMICS: GLOBAL ATMP MARKET
  • FIGURE 3 ATMP CLINICAL TRIALS FOR RARE DISEASES BY INDICATION, 2020
  • FIGURE 4 STEP ANALYSIS: GLOBAL ATMP MARKET, 2020-2031
  • FIGURE 5 SUPPLY CHAIN: GLOBAL ATMP MARKET
  • FIGURE 6 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V-SHAPED RECOVERY MODEL)
  • FIGURE 7 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U-SHAPED RECOVERY MODEL)
  • FIGURE 8 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L-SHAPED RECOVERY MODEL)
  • FIGURE 9 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L-SHAPED RECOVERY MODEL)
  • FIGURE 10 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), 2020-2031
  • FIGURE 11 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), 2021, 2026 AND 2031 (V-SHAPED RECOVERY MODEL)
  • FIGURE 12 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), 2021, 2026 AND 2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 13 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), 2021, 2026 AND 2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 14 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), 2021, 2026 AND 2031 (W SHAPED RECOVERY MODEL)
  • FIGURE 15 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031
  • FIGURE 16 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 17 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 18 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (L SHAPED RECOVERY MODEL)
  • FIGURE 19 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (W SHAPED RECOVERY MODEL)
  • FIGURE 20 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031
  • FIGURE 21 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (V SHAPED RECOVERY MODEL)
  • FIGURE 22 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (U SHAPED RECOVERY MODEL)
  • FIGURE 23 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (L SHAPED RECOVERY MODEL)
  • FIGURE 24 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (W SHAPED RECOVERY MODEL)
  • FIGURE 25 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), AND 2020-2031
  • FIGURE 26 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (V SHAPED RECOVERY MODEL)
  • FIGURE 27 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 28 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (L SHAPED RECOVERY MODEL)
  • FIGURE 29 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 30 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031
  • FIGURE 31 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 32 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 33 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 34 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 35 GLOBAL ATMP MARKET AND FORECAST: BY REGION, REVENUES ($ BN), 2021, 2026 AND 2031
  • FIGURE 36 GLOBAL ATMP MARKET FORECAST: MARKET SHARE (%), BY REGION, 2021, 2026 AND 2031
  • FIGURE 37 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), 2021, 2026 AND 203131 (V - SHAPED RECOVERY MODEL)
  • FIGURE 38 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), 2021, 2026 AND 2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 39 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), 2021, 2026 AND 2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 40 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), 2021, 2026 AND 2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 41 NORTH AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031
  • FIGURE 42 NORTH AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 43 NORTH AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 44 NORTH AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 45 NORTH AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 46 NORTH AMERICA ATMP MARKET AND FORECAST, BY COUNTRY: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 47 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 48 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (U - SHAPED MARKET RECOVERY MODEL)
  • FIGURE 49 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 50 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 51 U.S. ATMP MARKET AND FORECAST: REVENUE ($ BN), AND AGR (%), 2020-2031
  • FIGURE 52 U.S. ATMP MARKET AND FORECAST: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 53 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 54 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 55 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 56 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 57 CANADA ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031 131
  • FIGURE 58 CANADA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 59 CANADA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 60 CANADA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 61 CANADA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 62 CANADA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 63 EUROPE ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 64 EUROPE ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES HEALTHCARE ($ BN), 2021, 2026 AND 2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 65 EUROPE ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 66 EUROPE ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 67 EUROPE ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 68 EUROPE ATMP MARKET AND FORECAST, BY COUNTRY: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 69 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 70 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 71 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 72 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 73 GERMANY ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 74 GERMANY ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 75 GERMANY ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 76 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 77 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 78 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 79 U.K. ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 80 U.K. ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 81 U.K. ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 82 U.K. ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 83 U.K. ATMP MARKET AND FORECAST REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 84 U.K. ATMP MARKET AND FORECAST REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 85 FRANCE ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 86 FRANCE ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 87 FRANCE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 88 FRANCE ATMP MARKET AND FORECAST REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 89 FRANCE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 90 FRANCE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 91 ITALY ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 92 ITALY ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 93 ITALY ATMP MARKET AND FORECAST REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 94 ITALY ATMP MARKET AND FORECAST REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 95 ITALY ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 96 ITALY ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 97 SPAIN ATMP MARKET AND FORECAST: REVENUE ($ MN) AND AGR (%), 2020-2031
  • FIGURE 98 SPAIN ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 99 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 100 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 101 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 102 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 103 REST OF EUROPE ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 104 REST OF EUROPE ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 105 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 106 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 107 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 108 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 109 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 110 ASIA-PACIFIC ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 111 ASIA-PACIFIC ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 112 ASIA-PACIFIC ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 113 ASIA-PACIFIC ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 114 ASIA-PACIFIC ATMP MARKET AND FORECAST: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 115 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 116 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 117 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 118 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 119 JAPAN ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 120 JAPAN ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 121 JAPAN ATMP MARKET AND FORECAST REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 122 JAPAN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 123 JAPAN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 124 JAPAN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 125 CHINA ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 126 CHINA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 127 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 128 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 129 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 130 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 131 INDIA ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 132 INDIA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 133 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 134 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 135 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 136 INDIA ATMP MARKET AND FORECAST, ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 137 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 138 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN) 2021, 2026 AND 2031
  • FIGURE 139 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 140 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 141 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 142 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 143 LATIN AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 144 LATIN AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 145 LATIN AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 146 LATIN AMERICA ATMP MARKET AND FORECAST BY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 147 LATIN AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 148 LATIN AMERICA ATMP MARKET AND FORECAST: BY COUNTRY REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 149 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), 2021, 2026 AND 2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 150 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), 2021, 2026 AND 2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 151 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), 2021, 2026 AND 20311 (L - SHAPED RECOVERY MODEL)
  • FIGURE 152 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), 2021, 2026 AND 2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 153 BRAZIL ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 154 BRAZIL ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 155 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 156 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 157 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 158 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 159 MEXICO ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 160 MEXICO ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 161 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 162 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 163 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 164 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 165 REST OF LATIN AMERICA ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 166 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 167 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 168 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 169 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 170 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 171 MEA ATMP MARKET AND FORECAST: BY THERAPY PRODUCTS, REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 172 MEA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 173 MEA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 174 MEA ATMP MARKET AND FORECAST BY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 175 MEA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 176 MEA ATMP MARKET AND FORECAST: BY COUNTRY REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 177 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), 2021, 2026 AND 2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 178 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), 2021, 2026 AND 2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 179 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), 2021, 2026 AND 2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 180 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), 2021, 2026 AND 2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 181 UAE ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 182 UAE ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN) 2021, 2026 AND 2031
  • FIGURE 183 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 184 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 185 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 186 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 187 SOUTH AFRICA ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 188 SOUTH AFRICA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 189 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 190 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 191 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 192 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 193 REST OF MEA ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
  • FIGURE 194 REST OF MEA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
  • FIGURE 195 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
  • FIGURE 196 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
  • FIGURE 197 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
  • FIGURE 198 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
  • FIGURE 199 GLOBAL ATMP MARKET SHARE ANALYSIS (VALUE %), 2020
  • FIGURE 200 BLUEBIRD BIO, INC.: HISTORICAL REVENUE ($ TH), 2015-2019
  • FIGURE 201 BMS: NUTRITIONAL'S SEGMENT HISTORICAL REVENUE ($ MN), 2015-2019
  • FIGURE 202 GILEAD SCIENCES: HISTORICAL REVENUE ($ BN), 2015-2019
  • FIGURE 203 JCR PHARMACEUTICALS: HISTORICAL REVENUE ($ BN), 2015-2019
  • FIGURE 204 MEDIPOST: HISTORICAL REVENUE ($ MN), 2017-2019
  • FIGURE 205 NOVARTIS AG: HISTORICAL REVENUE ($ MN), 2015-2019
  • FIGURE 206 ORGANOGENESIS: HISTORICAL REVENUE ($ TH), 2017-2019
  • FIGURE 207 UNIQURE N.V.: HISTORICAL REVENUE ($ TH), 2015-2019
  • FIGURE 208 VERICEL CORPORATION: HISTORICAL REVENUE ($ TH), 2015-2019
  • FIGURE 209 GLOBAL ATMP: MARKET REVENUE AND FORECAST ($ BN) AND AGR (%), 2020-2031
  • FIGURE 210 GLOBAL ATMP MARKET, BY THERAPY PRODUCT MARKET SHARE (%), 2021, 2026 AND 2031
  • FIGURE 211 GLOBAL ATMP MARKET BY REGIONS, MARKET REVENUE ($ BN) 2021, 2026 AND 2031

Companies Profiled in the Report:

  • Bluebird bio, Inc.
  • Bristol Myers-Squibb
  • Gilead Sciences, Inc.
  • JCR Pharmaceuticals Co. Ltd.
  • Kolon TissueGene, Inc.
  • MEDIPOST
  • Novartis AG
  • Organogenesis Holdings, Inc.
  • PHARMICELL Co., Ltd.
  • Spark Therapeutics, Inc.
  • uniQure N.V.
  • Vericel Corporation

List of Companies Mentioned in the Report:

  • Aspen Global Incorporated
  • AveXis
  • Bayer
  • Bio Tissue Technologies
  • Biogen
  • Celgene Corporation
  • Century Therapeutics
  • Endocyte
  • Forty-Seven, Inc.
  • Fujifilm Cellular Dynamics
  • Genetix Pharmaceuticals, Inc
  • GlaxoSmithKline
  • IFM Tre, Inc.
  • Integra Lifesciences
  • Jazz Pharmaceuticals, Inc.
  • JCR Pharmaceuticals, Co., Ltd
  • Medidata Solutions
  • NuTech Medical
  • NuVasive, Inc.
  • Orchard Therapeutics, Inc
  • Osiris Therapeutics, Inc
  • Roche
  • Sarepta Therapeutics
  • SK Bioland
  • Tango Therapeutics
  • The Medicines Company
  • TissueGene, Inc
  • Tizona Therapeutics, Inc.
  • Versant Ventures
  • Zimmer Biomet

List of Organizations:

  • Alliance of Regenerative medicine
  • Bill & Melinda Gates Foundation
  • Centers for Disease Control and Prevention
  • Children's Hospital of Philadelphia
  • Cystic Fibrosis Foundation
  • European Medical Agency
  • International Diabetes Federation
  • Odylia Therapeutics
  • U.S. Food and Drug Administration
  • US National Institutes of Health
  • World Health Organization